期刊文献+

张家口地区98例汉族人乙型肝炎病毒基因分型与耐药变异

Genotypes and drug resistance mutations of hepatitis B virus in 98 infected patients of Han nationality in Zhangjiakou
原文传递
导出
摘要 目的:分析张家口地区汉族人乙型肝炎病毒基因分型与耐药变异。方法:分别采用巢式荧光实时定量PCR及荧光实时定量PCR检测张家口地区98例汉族乙肝病毒感染患者基因型及耐药变异,所有患者接受多拉米定抗病毒治疗。结果:张家口地区98例汉族人乙型肝炎病毒基因型主要以B型,C型,B+C混合型为主,其中B型29例(29.59%),C型30例(30.61%),B+C混合型39例(39.80%);发生YMDD变异总变异率为58.16%(57/98)。在发生YMDD变异者中,YVDD变异占61.40%(35/57),YIDD变异占38.60%(22/57)。基因型为B型者YMDD变异率为21.43%(21/98),C型者为33.67%(33/98),B+C混合型者为44.90%(44/98),三者之间差异有统计学意义(P<0.05)。结论:张家口地区汉族人乙型肝炎病毒基因型主要为B型,C型与B+C混合型;B+C混合型患者使用拉米夫定后发生YMDD变异率最高。 Objective: To analyze Hepatitis B virus (HBV) genotypes and drug resistance mutations among people in Zhangjiakou. Methods: The genotypes and drug resistant mutation of HBV in 98 infected cases of Han nationality in Zhangjiakou were detected by nested quantitative real-time PCR and real-time fluorescent PCR. Results: The main genotypes among the 98 cases in Zhangiiakou were genotype B (29.59%), C (30.61%) and B+C (39.80%). The total mutation rate of YMDD was 58.16% (57/98), among which, YVDD mutation accounted for 61.40% (35/57), and YIDD mutation was 38.60% (22/57). The YMDD mutation rate in genotype B was 21.43% (21/98), C was 33.67% (33/98) and B+C was 44.90% (44/98) respectively, and the difference among them was statistically significant (P〈0.05). Conclusion: The main HBV genotypes of Han nationality in Zhangjiakou are genotypes B, C and B+C, and the genotype B+C has the highest YMDD mutation rate after Lamivudine treatment.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第12期1550-1553,共4页 China Journal of General Surgery
关键词 肝炎 乙型 基因型 拉米夫定 流行病学 Hepatitis B Genotype Lamivudine Epidemiology
  • 相关文献

参考文献8

二级参考文献34

  • 1关剑,陈孝平,朱虹,罗顺锋.乙型肝炎病毒X蛋白上调肝癌多药耐药相关基因表达的研究[J].肝胆外科杂志,2004,12(3):214-216. 被引量:6
  • 2何延专,陆春雷,黄重敏,覃雪英,徐湘.苦参素联合促肝细胞生长素治疗慢性乙型肝炎肝纤维化106例[J].中西医结合肝病杂志,2006,16(3):174-175. 被引量:2
  • 3秦成勇,韩国庆.我国乙型肝炎的发病现状及治疗进展[J].医学研究杂志,2007,36(1):22-24. 被引量:30
  • 4Ohata K, Ichikawa T, Nakao K, et al. Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells [J]. FEBS Lett, 2003, 553(3) :304 -308.
  • 5Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer [ J ]. J Lab Clin Med, 2006, 147(1) :58 -66.
  • 6Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? [ J ]. Am J Gastroenterol, 2006, 101(3) :524-532.
  • 7Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma [J]. Clin Liver Dis, 2001, 5(1) :145 -159.
  • 8Teget hoff S, Behlke J, Scheidereit C. Tetrameric oligomerization of IkappaB kinase gamma ( IKKgamma ) is obligatory for IKK complex activity and NF-kappaB activation [ J ]. Mol Cell Biol, 2003, 23 (6) : 2029 -2041.
  • 9Um HR, Lim WC, Chae SY, et al. Raf-1 and protein kinase B regulate cell survival through the activation of NF-kappaB in hepatitis B virus X-expressing cells [ J ]. Virus Res, 2007, 125(1):1-8.
  • 10Park SG, Chung C, Kang H, et al. Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter [ J ]. J Biol Chem, 2006, 281(42):31770-31777.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部